Hemosiderosis News and Research

RSS
Novartis to present updates on broad cancer portfolio at ASH and SABCS symposiums

Novartis to present updates on broad cancer portfolio at ASH and SABCS symposiums

AMAG seeks FDA sNDA approval for Feraheme Injection

AMAG seeks FDA sNDA approval for Feraheme Injection

AMAG presents new data from two ferumoxytol phase III trials on IDA at ASH annual meeting

AMAG presents new data from two ferumoxytol phase III trials on IDA at ASH annual meeting

AMAG receives Swiss marketing authorization for ferumoxytol to treat iron deficiency anemia

AMAG receives Swiss marketing authorization for ferumoxytol to treat iron deficiency anemia

Positive preliminary results from Feraheme phase III study on iron deficiency anemia

Positive preliminary results from Feraheme phase III study on iron deficiency anemia

EC grants marketing authorization for AMAG's ferumoxytol to treat IDA

EC grants marketing authorization for AMAG's ferumoxytol to treat IDA

EMA CHMP recommends approval of AMAG’s ferumoxytol

EMA CHMP recommends approval of AMAG’s ferumoxytol

AMAG fourth quarter total revenues decrease to $14.9 million

AMAG fourth quarter total revenues decrease to $14.9 million

AMAG completes enrollment in Feraheme Phase III program for iron-deficiency anemia

AMAG completes enrollment in Feraheme Phase III program for iron-deficiency anemia

Novartis to showcase 160 presentations on breast cancer, hematological disease drugs at SABCS and ASH

Novartis to showcase 160 presentations on breast cancer, hematological disease drugs at SABCS and ASH

Feraheme as safe and effective as iron sucrose in patients with anemia, CKD

Feraheme as safe and effective as iron sucrose in patients with anemia, CKD

AMAG reports third quarter total revenues of $17.6 million

AMAG reports third quarter total revenues of $17.6 million

AMAG enters definitive merger agreement with Allos Therapeutics

AMAG enters definitive merger agreement with Allos Therapeutics

AMAG fourth quarter total revenues increase to $17.2 million

AMAG fourth quarter total revenues increase to $17.2 million

AMAG receives Health Canada Notice of Non-Compliance for Feraheme NDS

AMAG receives Health Canada Notice of Non-Compliance for Feraheme NDS

AMAG updates product label of Feraheme Injection

AMAG updates product label of Feraheme Injection

AMAG, Takeda provide regulatory and clinical update for Feraheme Injection

AMAG, Takeda provide regulatory and clinical update for Feraheme Injection

AMAG Pharmaceuticals releases safety update on Feraheme Injection

AMAG Pharmaceuticals releases safety update on Feraheme Injection

3Sbio submits registrational clinical trial application for Feraheme injection

3Sbio submits registrational clinical trial application for Feraheme injection